MedTrace Logo

The Safety and Antibody Response of the Nasal COV2 Vaccine Against the SARS-CoV-2 Virus

NCT06851611 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2025-12-08

No results posted yet for this study

Summary

COV2 is a nasal, investigational vaccine against COVID-19, based on a serotype 5 adenoviral vector producing the SARS-CoV-2 spike protein. In this trial, the primary comparison in terms of safety and immunogenicity will be between two different dose levels of COV2 booster vaccine (low, high), and two different administration methods (nasal drops, nasal spray). In addition, COV2 vaccine will also be evaluated in vaccine naive subjects.

Conditions

  • COVID19, Sars-Cov-2

Interventions

BIOLOGICAL

COVID-19 vaccine, low dose level

Test article

BIOLOGICAL

COVID-19 vaccine, high dose level

Test article

OTHER

Nasal Drops

Method of administration of test article

OTHER

Nasal Spray

Method of administration of test article

Sponsors & Collaborators

  • Rokote Laboratories Finland Oy

    lead INDUSTRY

Principal Investigators

  • Seppo Ylä-Herttuala, MD, PhD · Rokote Laboratories Finland Oy

  • Erkko Ylösmäki, PhD · Rokote Laboratories Finland Oy

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2025-01-21
Primary Completion
2025-06-25
Completion
2025-06-26

Countries

  • Finland

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06851611 on ClinicalTrials.gov